Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
A recent meta-analysis of Phase 3 trials reported increases in HR, based on single time point assessments, in the range of 14 bpm with both long- and short-acting GLP-1 RAs [15]
Brands must prioritize showing up in the right, high-intent moments for the GLP-1-conscious shopper
(ANVISA is the Brazilian Health Regulatory Agency, an independent federal authority linked to the Ministry of Health.) The drug uses the same active ingredient as innovator Novo Nordisk's #diabetes and #weight-loss drug Ozempic, whose #patent expired in Brazil in March 2025
This imbalance did not affect the primary endpoint and the incidence rate was higher in patients with a previous history of heart failure and independent of renal function at study baseline (57, 66, 67)
